Top ▲
Target id: 3071
Nomenclature: Plasmodium falciparum plasmepsin X
Abbreviated Name: PfPMX
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Plasmodium falciparum 3D7 | - | 573 | PMX | plasmepsin X |
Previous and Unofficial Names ![]() |
PMX | Pf3D7_08_v3:415,549..419,066(-) | PF08_0108 |
Database Links ![]() |
|
Alphafold | Q8IAS0 (Pf3D7) |
ChEMBL Target | CHEMBL4523390 (Pf3D7) |
PlasmoDB | PF3D7_0808200 (Pf3D7) |
UniProtKB | Q8IAS0 (Pf3D7) |
Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Whole Organism Assay Data Linked to This Target | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Malaria Pharmacology Comments |
The P. falciparum genome encodes 10 aspartic proteases, classed together as the plasmepsin family, which are involved in diverse cellular processes [2]. P. falciparum plasmepsin X (PfPMX) has emerged as a promising target for antimalarial drug development with studies demonstrating an essential role in merozoite invasion and egress of erythrocytes [5-6]. |
1. Ciana CL, Siegrist R, Aissaoui H, Marx L, Racine S, Meyer S, Binkert C, de Kanter R, Fischli C, Wittlin S et al.. (2013) Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold. Bioorg Med Chem Lett, 23 (3): 658-62. [PMID:23260352]
2. Coombs GH, Goldberg DE, Klemba M, Berry C, Kay J, Mottram JC. (2001) Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol, 17 (11): 532-7. [PMID:11872398]
3. De Lera Ruiz M., Favuzza P., Guo Z., Hu B. et al.. (2021) Antimalarial agents. Patent number: WO2021155612A1. Assignee: Merck Sharp & Dohme Corp., The Walter and Eliza Hall Insitute of Medical Research, MSD R&D. Priority date: 09/02/2020. Publication date: 12/08/2021.
4. Favuzza P, de Lera Ruiz M, Thompson JK, Triglia T, Ngo A, Steel RWJ, Vavrek M, Christensen J, Healer J, Boyce C et al.. (2020) Dual Plasmepsin-Targeting Antimalarial Agents Disrupt Multiple Stages of the Malaria Parasite Life Cycle. Cell Host Microbe, 27 (4): 642-658.e12. [PMID:32109369]
5. Nasamu AS, Glushakova S, Russo I, Vaupel B, Oksman A, Kim AS, Fremont DH, Tolia N, Beck JR, Meyers MJ et al.. (2017) Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion. Science, 358 (6362): 518-522. [PMID:29074774]
6. Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, Collins CR, Blackman MJ, Kursula I, Heussler V et al.. (2017) A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. Science, 358 (6362): 522-528. [PMID:29074775]
Peptidases and proteinases (Plasmodium spp.): Plasmodium falciparum plasmepsin X. Last modified on 31/03/2022. Accessed on 08/02/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=3071.